CyPass Micro-Stent

Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Managing glaucoma with surgical procedures (plural)The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
European study with microstent demonstrates lowered IOP, use of fewer drugsPatients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively
Exploring risk, reward in trabecular bypass, suprachoroidal devices
Exploring risk, reward in trabecular bypass, suprachoroidal devicesThough much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
MIGS devices lead glaucoma surgical innovation in 2016A single event stood out in everyone’s mind when Ophthalmology Times asked experts to think back on the year in glaucoma surgery: the July 29 approval by the U.S. Food and Drug Administration (FDA) of the CyPass Micro-Stent.
Glaucoma micro-stent’s 2-year data promisingTake-home: With the approval of a new surgical device aimed at lowering IOP, surgeons explore benefits of micro-stent implantation.
Microstent approval makes big news in glaucoma world
Microstent approval makes big news in glaucoma worldClinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
MIGS making big difference in glaucoma managementMicroinvasive glaucoma surgery devices already have transformed the management of glaucoma and will have a bigger impact in the future considering the options in the investigational pipeline and the opportunities they present.
Viscoelastic injection may improve microstent efficacyPatients receiving a sodium hyaluronate ophthalmic viscoelastic device injection showed a trend toward greater reduction in IOP than patients who received a microstent alone.